Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant

Go back to Preclinical Data Demonstrate Sotrovimab Retains Activity Against Key Omicron Mutations, New SARS-CoV-2 Variant
(NASDAQ: VIR) Delayed: 9.57 +0.41 (4.48%)
Previous Close $9.16    52 Week High
Open $9.29    52 Week Low
Day High $9.63    P/E N/A 
Day Low $9.16    EPS
Volume 1,793,539